These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A combination of portal vein stent insertion and endovascular iodine-125 seed-strip implantation, followed by transcatheter arterial chemoembolization with sorafenib for treatment of hepatocellular carcinoma-associated portal vein tumor thrombus.
    Author: Li S, Li B, Li L, Xu F, Yang X, Wang W.
    Journal: J Contemp Brachytherapy; 2021 Dec; 13(6):670-679. PubMed ID: 35079254.
    Abstract:
    PURPOSE: This study aimed to assess efficacy of portal vein stent (PVS) insertion and endovascular iodine-125 (125I) seed-strip implantation, followed by transcatheter arterial chemoembolization (TACE) with sorafenib (PVS-125I TACE-S) in patients with hepatocellular carcinoma (HCC)-associated type II or type III portal vein tumor thrombus (PVTT). MATERIAL AND METHODS: A retrospective study was performed on 53 consecutive patients with HCC and type II or type III PVTT, from May 2014 to July 2018. Patients were divided into 2 groups, including group A with 28 patients treated with PVS-125I TACE-S, and group B with 25 patients treated with TACE-S. Primary end-point was overall survival (OS), while secondary endpoints were hepatic function and disease control rate (DCR). Albumin-bilirubin (ALBI) score approach was used for evaluating liver function. Cox regression analysis was applied to identify factors associated with treatment outcomes. RESULTS: No pre-operative differences were found in ALBI scores between group A and group B (-2.57 ±0.42 vs. -2.61 ±0.38, p = 0.724), or in these scores at 1 month post-operatively (-2.62 ±0.46 vs. -2.20 ±0.59, p = 0.666). However, these scores were significantly different at 3 (-2.17 ±0.59 vs. -1.69 ±0.48, p = 0.007) and 6 (-2.28 ±1.23 vs. -1.47 ±0.31, p = 0.044) months post-operatively. In addition, group A exhibited higher DCR (71.4% vs. 44.0%, p = 0.043) after 6 months of treatment and extended OS duration (11.4 vs. 7.7 months, p = 0.007). A stratified analysis revealed that OS in patients with type II PVTT did not differ significantly (10.4 vs. 10.7 months, p = 0.689), but OS with type III varied significantly (11.5 vs. 7.5 months, p = 0.002). Multivariate analysis revealed that tumor size > 10 cm (p = 0.002) and multiple tumors (p = 0.022) were independent predictors for poor prognosis, whereas PVS-125I TACE-S was predictor for favorable patient's prognosis (p = 0.040). CONCLUSIONS: PVS-125I TACE-S represents a potentially viable strategy for improving hepatic functionality, DCR, and OS in HCC with type III PVTT compared with TACE-S alone.
    [Abstract] [Full Text] [Related] [New Search]